Conestoga Capital Advisors reported that Artivion, Inc. detracted from portfolio performance in the second quarter of 2026 after first-quarter stent graft sales fell short of expectations, citing slower-than-anticipated AMDS product adoption and softer international demand. The firm noted that reorder activity remains strong and expects adoption to accelerate as additional hospitals complete the approval process, maintaining that Artivion's expanding aortic portfolio and product pipeline provide meaningful long-term growth opportunities. Artivion shares closed at $26.55 on August 6, 2026, with a market capitalization of $1.29 billion, and have lost 32.45% over the past 52 weeks.
Artivion IncStent graft sales missed due to slower AMDS adoption and softer international demand.
